Download App

Log in to access Online Inquiry
Company Overview More
Shanghai Fuhong Hanlin Biotechnology Co., Ltd. is a Chinese company mainly engaged in the research, development, production and sales of monoclonal antibody products. The company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) bioanalogue HLX02, trimethoprim (adamumab) bioanalogue HLX03 and Avetine (bevacizumab) bioanalogue HLX04, as well as candidate biological innovation drugs. It includes HLX06 (a new type of VEGFR2 inhibitor), HLX07 (a kind of EGFR inhibitor), HLX10 (a new type of PD-1 inhibitor), HLX20 (a new type of PD-L1 inhibitor) and HLX22 (a new type of HER2 inhibitor). The company also provides related technical services. The company mainly operates in China and the United States.
CEO: Wenjie Zhang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > 02696 HENLIUS-B > Detailed Quotes

02696 HENLIUS-B

16.000+0.500+3.23%
Market Close 05/17 16:08 CCT
High
16.240
Open
16.220
Turnover
468.16K
Low
15.040
Pre Close
15.500
Volume
29.70K
Market Cap
8.70B
P/E(TTM)
Loss
52wk High
43.600
Shares
543.49M
P/E(Static)
Loss
52wk Low
14.380
Float Cap
2.61B
Bid/Ask %
-76.80%
Historical High
67.050
Shs Float
163.43M
Volume Ratio
0.09
Historical Low
14.380
Dividend TTM
--
Div Yield TTM
--
P/B
3.10
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
7.74%
Avg Price
15.762
Lot Size
100
Float Cap
2.61B
Bid/Ask %
-76.80%
Historical High
67.050
Shs Float
163.43M
Volume Ratio
0.09
Historical Low
14.380
Dividend TTM
--
P/B
3.10
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
7.74%
Avg Price
15.762
Lot Size
100
Price Forecast

No Data

News

Comment